Our results show that a reduction of glucosylceramidase protein levels and activity in fibroblasts from Gaucher disease, Parkinson’s disease with GBA mutations and non-manifesting carriers is because of a combination of decreases in GBA transcript levels and endoplasmic reticulum retention of glucosylceramidase protein. This evidence concerns the gene GBA1 and Parkinson disease.